Abstract
CEACAM5 is a cell surface biomarker protein with high expression in NSCLC. Tusamitamab ravtansine (tusa; SAR408701) consists of an antibody-drug conjugate of a humanized CEACAM5-specific monoclonal antibody linked to DM4, a potent anti-tubulin agent. In a phase I/II study (NCT02187848), tusa showed antitumor activity in pretreated pts with advanced non-squamous NSCLC and high CEACAM5 expression. Here, we report CEACAM5 expression levels, patterns, and correlation with demographic variables in these pts.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
